HLS Sees 2026 Adjusted EBITDA in Lower Half of Guidance
HLS Therapeutics expects 2026 adjusted EBITDA in the lower half of its $18.5 million-$21 million guidance range.
HLS Therapeutics expects 2026 adjusted EBITDA in the lower half of its $18.5 million-$21 million guidance range.